Fulvestrant

Drug Profile

Fulvestrant

Alternative Names: Faslodex; ICI 182780; ZD 182780; ZD 9238; ZM 182780

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Baylor Research Institute
  • Class Antineoplastics; Estradiol congeners; Estrenes
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Precocious puberty
  • No development reported Endometrial cancer
  • Discontinued Endometriosis

Most Recent Events

  • 01 Jan 2017 AstraZeneca completes the phase II FIRST trial in Breast Cancer (First-line therapy, Late-stage disease) in USA, Brazil, Czech Republic, United Kingdom, France, Italy, Poland and Spain (NCT00274469)
  • 08 Dec 2016 Efficacy data from the phase III FALCON trial in Breast cancer presented at the 39th Annual San Antonio Breast Cancer Symposium
  • 08 Oct 2016 AstraZeneca intends to submit application for label extension to regulatory body
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top